First Reta Phase III Results

These drugs tend to have milder side effects overall, and most issues can be reversed unless something rare happens, unlike surgery.

Fewer people will need surgery. Some may still use the medication beforehand and possibly afterward. Surgery becomes less essential overall. Accounts of surgery patients show its side effects are typically harsher than those from these medications.

These drugs are reducing the need for surgery. My own bypass years ago had manageable side effects, mainly the large loss itself. Surgeons might now combine the medications with procedures for very heavy patients, but I would skip surgery for typical obesity cases if these options had existed earlier.

I get the dysesthesia effect but the gains far outweigh it.

Many regain the weight or more after surgery. With this medication used properly there is room to adjust eating habits instead of being physically restricted.

I regained only about 100 pounds from my lowest point rather than everything. Tirzepatide has changed things for me and I am looking forward to trying retatrutide.

I reached about 55 percent of starting weight lost and came close to goal. That was better than average, though keeping it off has been the harder part. Clinical research interests me and I am eager for more retatrutide data, including the Phase 2 NEJM paper.

That dropout pattern seems more psychological and social, with families reacting strongly to the sudden visible change in someone who had been heavy for years.

The program tests 2 mg, 4 mg, 6 mg, 9 mg, and 12 mg.

I see something similar with my mother-in-law who has long been very heavy. She lists her health issues but hesitates on the medication despite knowing weight loss would help. Conversations stay careful because the topic is sensitive.

The basket design is clever for separating effects on weight, apnea, and osteoarthritis. Weight loss obviously eases knee pain, yet the setup tries to isolate the drug's direct impact.

Would an oral version make it easier for her to start?

I see many gastric bypass patients with ongoing pain and complications that cannot be undone, though some do well and diabetes often improves. Still, medication seems preferable when possible.

She already uses injections for diabetes, but starting with research-grade material might not appeal to her.

They were under medical supervision, so the full picture may need the published data.

Why not try the full 15 mg tirzepatide dose before switching, or was that ruled out by the side effects at 12.5 mg? I recently increased and noticed more sides after a smooth period at lower levels.

That participant behavior concerns me for study integrity. Better verification of dosing would help, and skipping doses selfishly affects the data. It also hints that maintenance needs may be lower than peak trial doses.

These outcomes are what I was hoping to see. I have been holding material until the Phase 3 data arrived.

Sides became hard to manage past 7.5 mg, with very low calorie intake and returning food noise. The plateau started before any other additions. I may test the higher tirzepatide dose once more before deciding.

Hard to trust participants who waste the opportunity and break the agreement. They should face consequences.

ARA-290 has helped with allodynia in my experience and shows potential for dysesthesia and other nerve pain as well.

It could also be the highest safe level. Going further might eliminate appetite entirely and lead to dangerous under-eating.

Growth hormone compounds increased my hunger and worked against the loss, so I paused them.

Thanks. The plateau predates the growth hormone addition. Scale movement is not the main concern, but lack of visible progress is worrying.

Trial entry required BMI of at least 27, and those who dropped for losing too much tended to start with lower BMI, which fits the longer study duration.

Helpful detail. I reached goal on retatrutide and am figuring out maintenance while trying to regain some muscle. Even with adjusted dosing and occasional higher intake I am still below maintenance calories.

Glad this forum exists. The same sensations appeared during another trial and staff dismissed them. It felt like a mix of both effects but mostly dysesthesia. Tirzepatide has not produced it so far.

When you say maxing out the signal, do you mean constant hunger or the opposite?